However, while these interactions have been described to occur between PTHR1 and β2-AR in the context of intermittent PTH treatment, it is still unknown whether breast cancer-secreted PTHrP can elicit the same response in the context of bone metastatic disease. Here, ADRB2 is linked to breast carcinoma.